Literature DB >> 2120579

Production of an abnormal mu chain with a shortened VHIV subgroup variable region in a Burkitt's lymphoma cell line.

M Cogné1, S Mounir, T Mahdi, J L Preud'homme, F Nau, P Guglielmi.   

Abstract

The Burkitt's lymphoma cell line Ly66 produces a short mu chain which lacks 4 kDa in apparent molecular mass. Study of the corresponding messenger RNA showed it to be 0.3 kb shorter than normal mu transcripts. The cDNA sequence of the mu transcripts began by a short VH region consisting of the first one-third of a VHIV subgroup gene segment. It was followed by a normal mu constant region. This VH region coded for 38 amino acids, thus differing from two truncated VHIV regions previously reported in other Burkitt's lymphoma cell lines, which were interrupted at codon +26 by an alternate splicing event. In addition, the Ly66 variable sequence bore several point mutations and contained two potential N-glycosylation sites.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2120579     DOI: 10.1016/0161-5890(90)90160-2

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  5 in total

1.  Structure and expression of the mb-1 transcript in human lymphoid cells.

Authors:  I Leduc; J L Preud'homme; M Cogné
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

2.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1992-03-11       Impact factor: 16.971

3.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1991-06-25       Impact factor: 16.971

4.  An aberrant splicing using a 3' cryptic splice site within the CH1 exon induces truncated mu-chain production.

Authors:  T Komori; H Sugiyama
Journal:  Immunology       Date:  1995-05       Impact factor: 7.397

5.  Burkitt's lymphoma is a malignancy of mature B cells expressing somatically mutated V region genes.

Authors:  U Klein; G Klein; B Ehlin-Henriksson; K Rajewsky; R Küppers
Journal:  Mol Med       Date:  1995-07       Impact factor: 6.354

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.